Gemifloxacin for the Treatment of Respiratory Tract Infections: In Vitro Susceptibility, Pharmacokinetics and Pharmacodynamics, Clinical Efficacy, and Safety

This publication has 94 references indexed in Scilit:

• Assessment of pharmacokinetic–pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae
  Diagnostic Microbiology and Infectious Disease, 2005
• Fluoroquinolone Resistance inStreptococcus pneumoniae: Evidence ThatgyrAMutations Arise at a Lower Rate and That Mutation ingyrAorparCPredisposes to Further Mutation
  Microbial Drug Resistance, 2003
• Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin
  Journal of Antimicrobial Chemotherapy, 2001
• Discovery of gemifloxacin (Factive, LB20304a): a quinolone of new a generation
  Il Farmaco, 2001
• Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses
  International Journal of Antimicrobial Agents, 2000
• A Comparative In Vitro Surveillance Study of Gemifloxacin Activities against 2,632 Recent Streptococcus pneumoniae Isolates from across Europe, North America, and South America
  Antimicrobial Agents and Chemotherapy, 2000
• The safety profile of the fluoroquinolones
  Clinical Therapeutics, 2000
• Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
  Journal of Antimicrobial Chemotherapy, 2000
• Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.
  Journal of Antimicrobial Chemotherapy, 2000
• Interactions of Fluoroquinolones with Other Drugs: Mechanisms, Variability, Clinical Significance, and Management
  Clinical Infectious Diseases, 1992